NEW YORK (GenomeWeb News) – Bio-Reference Laboratories today said that revenues for its fiscal fourth quarter climbed 18 percent year over year, in spite of a reduction in reimbursements.

For the three months ended Oct. 31, Bio-Reference posted $192.2 million in revenues, compared to $163.5 million a year ago, and edging out the consensus Wall Street estimate of $192.0 million.

The clinical laboratory said that revenue per patient inched up to $80.80 from $79.66, while the number of patients served increased to 2,350 from 2,039.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.